SYRS News and Press, Syros Pharmaceuticals Inc. From 08/06/19

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference. Details are as follows: ...

Syros Pharmaceuticals (SYRS) Q2 2019 Earnings Conference Call August 1, 2019 08:30 ET Company Participants Naomi Aoki - Investor Relations Nancy Simonian - Chief Executive Officer Joe Ferra - Chief Financial Officer David Roth - Chief Medical Officer Eric Olson - Chief Scient...

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q2 GAAP EPS of -$0.47 misses by $0.05 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Enrollment Initiated in Phase 2 Trial Cohort Evaluating SY-1425 and Azacitidine in Genomically Defined Patients with Relapsed or Refractory Acute Myeloid Leukemia Multiple Clinical Data Readouts Expected for SY-1425 and SY-1365 in 2019 and 2020 Management to Host Conference Call...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 1, 2019 to report its second quarter 2019 financial results and provide ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes, today announced the appointment of Alice Tsang Shaw, M.D., Ph.D., to the Company’s Board of Directors. Dr. Shaw is a highly respected oncologis...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Details are as follo...

"During the flames of controversy, opinions, mass disputes, conflict, and world news, sometimes the most precious, refreshing, peaceful words to hear amidst all the chaos are simply and humbly 'I don't know .” ― Criss Jami Today we check back in on the progress of a small de...

SY-1365 Currently in Phase 1 Clinical Trial in Relapsed and Treatment-Resistant Ovarian and Breast Cancer Patients Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the online publication of a new manus...